4.7 Article

Predictors of recurrence in bipolar disorders in Spain (PREBIS study data)

期刊

JOURNAL OF AFFECTIVE DISORDERS
卷 141, 期 2-3, 页码 406-414

出版社

ELSEVIER
DOI: 10.1016/j.jad.2012.03.009

关键词

Bipolar disorder; Follow-up study; Recurrence; Predictors; Outcome; Urbanicity

资金

  1. AstraZeneca
  2. Bristol-Myers Squibb
  3. Eli Lilly
  4. Janssen-Cilag
  5. Pfizer
  6. Glaxo-Smithkline
  7. Cephalon
  8. Lundbeck
  9. Almirall (Barcelona, Spain)
  10. Astra-Zeneca (Madrid, Spain)
  11. Eli Lilly (IN,USA)
  12. Glaxo-Smith-Kline (Madrid, Spain)
  13. Lundbeck (Barcelona, Spain)
  14. Pfizer (Madrid, Spain)
  15. Sanofi-Aventis (Paris, France)
  16. MSD (Barcelona, Spain)
  17. BMS (Barcelona, Spain)
  18. Janssen (Barcelona, Spain)
  19. Boehringer Ingelheim (Barcelona, Spain)
  20. Lilly
  21. Bristol-Myers
  22. Wyeth
  23. Forest Research Institute
  24. Gedeon Richter
  25. Jazz
  26. Merck Sharp Dohme
  27. Novartis
  28. Otsuka
  29. Pfizer Inc
  30. Sanofi-Aventis
  31. Servier
  32. Takeda
  33. UBC
  34. GlaxoSmithKline
  35. Astra-Zeneca
  36. Janssen

向作者/读者索取更多资源

Objective: The objective of this study was to evaluate demographic, psychosocial and clinical predictors of mood recurrences in bipolar disorder (BD) euthymic outpatients followed-up for 12 months in a naturalistic setting. Methods: The study included 595 consecutive BD patients, diagnosed according to DSM-IV-TR criteria, in clinical remission at baseline. Quarterly assessments were scheduled. Clinical evaluation as well as mood and functioning psychometric evaluations were performed. We applied logistic regression analysis to determine predictors of presenting an affective recurrence, and Cox regression analysis to examine the association between individual predictors and time to affective recurrence. Results: Of the 593 patients finally included (60% women, 84.5% BD I), 141 (23.78%) had at least a recurrence during the 12 months follow-up. Time until 25% of the patients experienced a recurrence was 12 months (95% CI: 9.14-undetermined). In multivariate analysis, factors significantly related to relapse were living setting (p = 0.002) and total number of previous episodes (p = 0.01). Residents in mixed urban/rural catchment areas had 57% more risk than dwellers of cities with more than 100,000 people, and a higher number of previous episodes also increased the relapse risk. A shorter time to relapse was related to job status (p = 0.004) and to living setting (p = 0.002). Conclusion: In our sample, living in environments of less than 100,000 inhabitants and having more previous affective episodes were related to an increased relapse risk in BD, and job status and living setting were related to a shorter time to relapse. Limitations: No specific contemporary practice guidelines were used. Drug treatment and plasma levels, although measured, were not registered. (C) 2012 Elsevier B. V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据